2021. RFLSP.Russian.Finnish.Life.Science.Industry.EN

More documents

Recommendations

Info

2.46 PPDPCompany profileEnterprise for diagnostic medicine production ("PPDP" LLC) wascreated in order to meet the needs of practical healthcare withmodern effective medicaments for diagnostics of influenza A andB viruses and other flu diseases: parainfluenza viruses of 1, 2 and3 types, RSV and adenoviruses. The production is based on yearsof scientific research and production experience of biotechnologylaboratory and diagnostic products in the Smorodintsev ResearchInstitute of Influenza of the Ministry of Healthcare of Russia,which is one of the founders of the company.Diagnostic products developed by "PPDP" LLC are widely used inpublic healthcare practice for different immunologicalresearches: Immunofluorescence analysis (IFL), Immunoenzymeanalysis (ELISA), hemagglutination inhibition analysis. Thecompany produces all the necessary range of immunodiagnosticproducts. This made it possible to carry out laboratorysurveillance for influenza and acute respiratory viral infections inRussia and CIS countries in accordance with the recommendationsof the World Health Organization (WHO).Products and servicesThe company produces a wide range of modern products for thediagnosis of influenza viruses and other acute respiratory viruses,including:§ Fluorescent immunoglobulins for detection of viralantigen in clinical materials;§ Immunoenzyme test-systems for detection of viralantigens and increase in antibodies in the sera ofreturnees;§ Diagnosticums and diagnostic sera for antibody detectionand virus identification in hemagglutination inhibitionassay and neutralization reaction;§ Monoclonal antibodies for immunodiagnostic studies.Key figures:Founded: 29.07.2013Turnover (2020): 37,982 mln. RUBEmployees (2020): 3INN: 7813567247Type of company: micro enterpriseProduct code: 21.20 Production ofmedicines and materials used for medicalpurposesContact information:Prof. Popova Str., 15/17197376 St. Petersburg, Russia+7 (812) 309 85 32ppdp@influenza.spb.ruhttp://ppdp-spb.com/Contact person: Grudinin Mikhail – GeneralDirector134RUSSIAN-FINNISH LIFE SCIENCE INDUSTRYResearch and export directory
2.47 RADUGA LAKHTACompany profileRaduga Production (Raduga Lakhta, LLC) is a modern full cyclepharmaceutical production plant. Raduga Production plant isconnected by long-term partnership with such companies asRoche, Ipsen, KRKA, which manufacture their products at thefacilities of the plant.Continuous improvement and striving to meet internationalquality standards are priority goals for the company which allowto expand cooperation with leading European companies. Since2012, Raduga Production has successfully passed audits ofmedicines manufacturers such as Actavis, AstraZeneca, Ipsen,KRKA, Roche, Sandoz. Over the years, the company hasaccumulated significant experience in implementinginternational projects, advanced technologies with full cycleproduction, control and quality assurance of the final product.Products and servicesThe company manufactures medicines in solid dosage forms -tablets, capsul-coated tablets, hard gelatin capsules, and alsoprovides services for primary and secondary packaging of a widerange of dosage forms, including injectable forms.Key figures:Founded: 18.12.2012Turnover (2020): 1,449 mln. RUBEmployees (2020): -INN: 7814558051Type of company: micro enterpriseProduct code: 21.1 Manufacturing ofpharmaceutical substancesContact information:3 Konnaia Lakhta Str., 48/7, lit. A,premises 1-N 307 rm 1197229 St. Petersburg, Russia+7 (812) 324 31 86info@raduga-production.ruhttp://raduga-production.ru/Contact person: Grigoriev Ilia – GeneralDirectorRUSSIAN-FINNISH LIFE SCIENCE INDUSTRYResearch and export directory135
Page 2 and 3:
This publication was developed in t
Page 4 and 5:
1.5 Events ........................
Page 6 and 7:
2.42 PHARM-HOLDING ................
Page 8 and 9:
1 PART 1: MARKET RESEARCH1.1 Indust
Page 10 and 11:
The Russian pharmaceutical market i
Page 12 and 13:
Imported/localized drugs sales rati
Page 14 and 15:
In 2020, the share of original drug
Page 16 and 17:
1.1.2 Commercial segment of the Rus
Page 18 and 19:
1.1.3 Drug reimbursement segmentAcc
Page 20 and 21:
1.1.4 Segment of purchases of drugs
Page 22 and 23:
1.1.5 Dietary supplements segmentAc
Page 24 and 25:
The development of the innovative d
Page 26 and 27:
Dynamics of pharmaceutical products
Page 28 and 29:
§ the term of the SPIC has been ex
Page 30 and 31:
The Pharma-2030 Strategy elaboratio
Page 32 and 33:
presence of viral RNA and antibodie
Page 34 and 35:
§ training system in the field of
Page 36 and 37:
counter external risks (for example
Page 38 and 39:
1.3.2 The Pavlov First Saint Peters
Page 40 and 41:
1.3.3 North-Western State Medical U
Page 42 and 43:
1.3.4 Military Medical Academy name
Page 44 and 45:
1.3.6 Saint-Petersburg State Instit
Page 46 and 47:
1.3.7 Peter the Great St. Petersbur
Page 48 and 49:
1.3.9 Saint-Petersburg Medico-Socia
Page 50 and 51:
1.4.2 Almazov National Medical Rese
Page 52 and 53:
1.4.4 Institute of Cytology RASInst
Page 54 and 55:
1.4.6 Kashkin Research Institute of
Page 56 and 57:
1.4.8 Research Institute of Hygiene
Page 58 and 59:
1.4.10 Saint-Petersburg Pasteur Ins
Page 60 and 61:
Contact informationBekhtereva Str.,
Page 62 and 63:
The Institute has Influenza and ARD
Page 64 and 65:
1.4.14 V. M. Gorbatov Federal Resea
Page 66 and 67:
1.5 Events1.5.1 Events calendarDate
Page 68 and 69:
1.5.2.2 Nordic Life Science DaysNor
Page 70 and 71:
1.5.2.4 HealthBIOThe HealthBIO even
Page 72 and 73:
1.5.2.6 BioJapanBioJapan has played
Page 74 and 75:
1.5.2.8 CPhI WorldwideCPhI is an es
Page 76 and 77:
1.5.2.10 INTERPHEX Japan 2021INTERP
Page 78 and 79:
1.5.3.2 IPhEB RussiaIPhEB Russia is
Page 80 and 81:
1.6 Clusters and associations1.6.1
Page 82 and 83:
1.6.3 Cluster of medical, environme
Page 84 and 85: 1.7 Cases and success stories1.7.1
Page 86 and 87: 1.8 Information sources1.8.1 Strate
Page 88 and 89: § DSM Group. Analytical report “
Page 90 and 91: 2.2 ALKOR BIOCompany profileThe St.
Page 92 and 93: 2.4 AMBERCompany profileAmber Group
Page 94 and 95: 2.6 AVENACompany profileAvena compa
Page 96 and 97: 2.8 BELKOZINCompany profileBelkozin
Page 98 and 99: 2.10 BIOCADCompany profileBiocad is
Page 100 and 101: 2.12 BIOPHARMOSCompany profileBioPh
Page 102 and 103: 2.14 BIOTECHCompany profileBiotech
Page 104 and 105: 2.16 CYTOMEDCompany profileCytomed
Page 106 and 107: 2.18 EKVUSCompany profile“Ekvus
Page 108 and 109: 2.20 FARMAKOGENCompany profileFarma
Page 110 and 111: 2.22 FRAMEBIOTEKCompany profileFram
Page 112 and 113: 2.24 GEROPHARMCompany profileGeroph
Page 114 and 115: 2.26 GROTEXCompany profileSolopharm
Page 116 and 117: 2.28 HARMSCompany profileHistory of
Page 118 and 119: 2.30 LEKKERCompany profileThe histo
Page 120 and 121: 2.32 NEPHRONCompany profileResearch
Page 122 and 123: 2.34 NIKACompany profileNika Factor
Page 124 and 125: 2.36 PHARM. ASSOCIATION NAMED FOR P
Page 126 and 127: 2.38 PHARMA VAMCompany profilePharm
Page 128 and 129: 2.40 PHARMAKOR PRODUCTIONCompany pr
Page 130 and 131: 2.42 PHARM-HOLDINGCompany profilePh
Page 132 and 133: 2.44 PHARMSYNTHEZCompany profilePha
Page 136 and 137: 2.48 RESEARCH INSTITUTE OF INNOVATI
Page 138 and 139: 2.50 SEVERNAIA ZVEZDACompany profil
Page 140 and 141: 2.52 VITAL DEVELOPMENT CORPORATIONC
Page 142 and 143: For notes142RUSSIAN-FINNISH LIFE SC
Page 144: 144RUSSIAN-FINNISH LIFE SCIENCE IND
show all

2021. RFLSP.Russian.Finnish.Life.Science.Industry.EN

Create successful ePaper yourself

Delete template?

Save as template?